Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 9/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 11/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 11/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23396776 | 0.91 | WNT3A (0.42) | WNT3AP2RX3P2RX2 | |
| SCHEMBL18743502 | 0.90 | WNT3A (0.44) | WNT3AP2RX3P2RX2 | |
| SCHEMBL18742873 | 0.89 | WNT3A (0.41) | WNT3A | |
| SCHEMBL18743498 | 0.87 | GRIN2D (0.45) | WNT3A | |
| SCHEMBL18742909 | 0.85 | WNT3A (0.43) | WNT3AP2RX3P2RX2 | |
| SCHEMBL18742917 | 0.84 | WNT3A (0.48) | WNT3A | |
| SCHEMBL18743501 | 0.82 | WNT3A (0.43) | WNT3A | |
| SCHEMBL18742889 | 0.80 | P2RX3 (0.42) | WNT3AP2RX3P2RX2 | |
| SCHEMBL18742890 | 0.78 | WNT3A (0.43) | WNT3AP2RX3P2RX2 | |
| SCHEMBL18742903 | 0.77 | WNT3A (0.43) | WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359154-B1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2021-05-26 | — | — | EP | disclosed |
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-02-13 | — | — | US | disclosed |
| US-10450300-B2 | Wnt signaling pathway inhibitors and therapeutic applications thereof | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-10-22 | — | — | US | disclosed |
| WO-2017062688-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450300-B2 | Wnt signaling pathway inhibitors and therapeutic applications thereof | WNT1, WNT3A, CTNNB1 | WNT3A 2/4885P2RX3 3485/4885P2RX2 3267/4885 |
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | WNT1, WNT3A, CTNNB1 | WNT3A 2/4885P2RX3 3485/4885P2RX2 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.